Literature DB >> 11376112

The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.

J A Visser1, R Olaso, M Verhoef-Post, P Kramer, A P Themmen, H A Ingraham.   

Abstract

Müllerian inhibiting substance (MIS or anti-Müllerian hormone) is a member of the transforming growth factor-beta family and plays a pivotal role in proper male sexual differentiation. Members of this family signal by the assembly of two related serine/threonine kinase receptors, referred to as type I or type II receptors, and downstream cytoplasmic Smad effector proteins. Although the MIS type II receptor (MISRII) has been identified, the identity of the type I receptor is unclear. Here we report that MIS activates a bone morphogenetic protein-like signaling pathway, which is solely dependent on the presence of the MISRII and bioactive MIS ligand. Among the multiple type I candidates tested, only ALK2 resulted in significant enhancement of the MIS signaling response. Furthermore, dominant-negative and antisense strategies showed that ALK2 is essential for MIS-induced signaling in two independent assays, the cellular Tlx-2 reporter gene assay and the Müllerian duct regression organ culture assay. In contrast, ALK6, the other candidate MIS type I receptor, was not required. Expression analyses revealed that ALK2 is present in all MIS target tissues including the mesenchyme surrounding the epithelial Müllerian duct. Collectively, we conclude that MIS employs a bone morphogenetic protein-like signaling pathway and uses ALK2 as its type I receptor. The use of this ubiquitously expressed type I receptor underscores the role of the MIS ligand and the MIS type II receptor in establishing the specificity of the MIS signaling cascade.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376112     DOI: 10.1210/mend.15.6.0645

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  43 in total

1.  Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta.

Authors:  Nathalie di Clemente; Soazik P Jamin; Alexey Lugovskoy; Paul Carmillo; Christian Ehrenfels; Jean-Yves Picard; Adrian Whitty; Nathalie Josso; R Blake Pepinsky; Richard L Cate
Journal:  Mol Endocrinol       Date:  2010-09-22

2.  Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.

Authors:  Katia Meirelles; Leo Andrew Benedict; David Dombkowski; David Pepin; Frederic I Preffer; Jose Teixeira; Pradeep Singh Tanwar; Robert H Young; David T MacLaughlin; Patricia K Donahoe; Xiaolong Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-27       Impact factor: 11.205

3.  Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

Authors:  Elizabeth J Renaud; David T MacLaughlin; Esther Oliva; Bo R Rueda; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-23       Impact factor: 11.205

4.  Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.

Authors:  E Basal; T Ayeni; Q Zhang; C Langstraat; P K Donahoe; D Pepin; X Yin; E Leof; W Cliby
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

5.  Mullerian inhibiting substance recruits ALK3 to regulate Leydig cell differentiation.

Authors:  Xiufeng Wu; Ningning Zhang; Mary M Lee
Journal:  Endocrinology       Date:  2012-08-07       Impact factor: 4.736

Review 6.  The TGF-β Family in the Reproductive Tract.

Authors:  Diana Monsivais; Martin M Matzuk; Stephanie A Pangas
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-10-03       Impact factor: 10.005

7.  Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.

Authors:  V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

8.  Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

Authors:  Henry L Chang; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Xianlin Li; Xiaolong Wei; David T MacLaughlin; Patricia K Donahoe
Journal:  Gynecol Oncol       Date:  2010-11-06       Impact factor: 5.482

9.  AMH induces mesonephric cell migration in XX gonads.

Authors:  Andrea J Ross; Christopher Tilman; Humphrey Yao; David MacLaughlin; Blanche Capel
Journal:  Mol Cell Endocrinol       Date:  2003-12-15       Impact factor: 4.102

10.  Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells.

Authors:  Peter J Malloy; Lihong Peng; Jining Wang; David Feldman
Journal:  Endocrinology       Date:  2008-12-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.